Effective Synergy of Sorafenib and Nutrient Shortage in Inducing Melanoma Cell Death through Energy Stress.
apoptosis
autophagy
energy stress
melanoma
sorafenib
Journal
Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052
Informations de publication
Date de publication:
06 03 2020
06 03 2020
Historique:
received:
27
01
2020
revised:
28
02
2020
accepted:
02
03
2020
entrez:
12
3
2020
pubmed:
12
3
2020
medline:
12
3
2021
Statut:
epublish
Résumé
Skin melanoma is one of the most aggressive and difficult-to-treat human malignancies, characterized by poor survival rates, thus requiring urgent novel therapeutic approaches. Although metabolic reprogramming has represented so far, a cancer hallmark, accumulating data indicate a high plasticity of cancer cells in modulating cellular metabolism to adapt to a heterogeneous and continuously changing microenvironment, suggesting a novel therapeutic approach for dietary manipulation in cancer therapy. To this aim, we exposed melanoma cells to combined nutrient-restriction/sorafenib. Results indicate that cell death was efficiently induced, with apoptosis representing the prominent feature. In contrast, autophagy was blocked in the final stage by this treatment, similarly to chloroquine, which also enhanced melanoma cell sensitization to combined treatment. Energy stress was evidenced by associated treatment with mitochondrial dysfunction and glycolysis impairment, suggesting metabolic stress determining melanoma cell death. A reduction of tumor growth after cycles of intermittent fasting together with sorafenib treatment was also observed in vivo, reinforcing that the nutrient shortage can potentiate anti-melanoma therapy. Our findings showed that the restriction of nutrients by intermittent fasting potentiates the effects of sorafenib due to the modulation of cellular metabolism, suggesting that it is possible to harness the energy of cancer cells for the treatment of melanoma.
Identifiants
pubmed: 32155825
pii: cells9030640
doi: 10.3390/cells9030640
pmc: PMC7140454
pii:
doi:
Substances chimiques
Antineoplastic Agents
0
Sorafenib
9ZOQ3TZI87
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
J Biol Chem. 2005 Sep 30;280(39):33280-8
pubmed: 16051596
Mol Cancer Ther. 2016 May;15(5):774-82
pubmed: 27197257
Oncogene. 2017 Jan 12;36(2):147-157
pubmed: 27270434
Cell Death Differ. 2015 Jun;22(6):946-58
pubmed: 25361077
J Biol Chem. 2017 Sep 8;292(36):15105-15120
pubmed: 28673964
Cell Death Dis. 2019 Nov 28;10(12):902
pubmed: 31780644
Cancer Treat Rev. 2018 Jul;68:16-24
pubmed: 29783126
Nat Rev Mol Cell Biol. 2014 Feb;15(2):81-94
pubmed: 24401948
Proc Natl Acad Sci U S A. 2010 May 11;107(19):8788-93
pubmed: 20421486
Future Oncol. 2013 Jul;9(7):959-76
pubmed: 23837760
J Proteome Res. 2012 Mar 2;11(3):1609-20
pubmed: 22268697
Oncotarget. 2015 Nov 10;6(35):37066-82
pubmed: 26416459
Cell Death Differ. 2012 Sep;19(9):1495-504
pubmed: 22441670
Autophagy. 2015;11(3):581-2
pubmed: 25837021
Chem Biol Interact. 2018 Feb 1;281:89-97
pubmed: 29273566
Int J Cancer. 2012 Aug 1;131(3):548-57
pubmed: 21858812
Amino Acids. 2014 Dec;46(12):2767-76
pubmed: 25218134
Dev Cell. 2014 Dec 22;31(6):734-46
pubmed: 25499913
Cell Cycle. 2010 Sep 1;9(17):3506-14
pubmed: 20818174
Clin Cancer Res. 2011 Apr 15;17(8):2216-26
pubmed: 21270111
Cell Chem Biol. 2017 Jul 20;24(7):813-824.e4
pubmed: 28625738
Anticancer Res. 2014 Nov;34(11):6417-22
pubmed: 25368241
Cell Mol Neurobiol. 2016 Oct;36(7):1197-208
pubmed: 26971793
J Immunother Cancer. 2018 May 16;6(1):39
pubmed: 29769148
Pharmacol Rev. 2016 Jan;68(1):20-48
pubmed: 26589414
Mol Med. 2012 Feb 10;18:19-28
pubmed: 21979753
Cancer Cell. 2012 Mar 20;21(3):297-308
pubmed: 22439925
Clin Cancer Res. 2002 Nov;8(11):3527-38
pubmed: 12429644
J Biol Chem. 2005 Mar 18;280(11):10491-500
pubmed: 15637055
Science. 2012 Aug 31;337(6098):1062-5
pubmed: 22936770
Int J Cancer. 2010 Jan 1;126(1):303-4
pubmed: 19859913
Mol Med Rep. 2015 Aug;12(2):1645-52
pubmed: 25891159
Clin Transl Oncol. 2016 Sep;18(9):863-71
pubmed: 26825657
Autophagy. 2012 Aug;8(8):1255-7
pubmed: 22575990
Biochem Biophys Res Commun. 2017 Mar 25;485(1):16-22
pubmed: 27693581
Clin Transl Oncol. 2015 Feb;17(2):121-32
pubmed: 25037851
Breast Cancer Res Treat. 2013 Aug;141(1):67-78
pubmed: 23963659
Nucl Med Biol. 2007 Apr;34(3):229-32
pubmed: 17383571
Biochim Biophys Acta. 2013 Nov;1830(11):5175-83
pubmed: 23872355
Trends Mol Med. 2015 Mar;21(3):164-71
pubmed: 25618774
Semin Cell Dev Biol. 2015 Mar;39:63-9
pubmed: 25736836
Br J Pharmacol. 2016 Mar;173(6):970-9
pubmed: 26750865
PLoS One. 2012;7(9):e44603
pubmed: 22984531
Oncotarget. 2015 May 20;6(14):11806-19
pubmed: 25909219
Mol Cell Oncol. 2015 Jan 26;2(3):e995016
pubmed: 27308477
Cell Metab. 2014 Feb 4;19(2):181-92
pubmed: 24440038
Oncoimmunology. 2019 Apr 3;8(7):1591878
pubmed: 31143510
Semin Cancer Biol. 2013 Oct;23(5):337-43
pubmed: 23856558
J Cancer Res Ther. 2009 Sep;5 Suppl 1:S21-6
pubmed: 20009289
Nat Rev Cancer. 2011 May;11(5):325-37
pubmed: 21508971
Genes Dev. 2012 May 1;26(9):877-90
pubmed: 22549953
Autophagy. 2013 Dec;9(12):2056-68
pubmed: 24157892
Ann Oncol. 2014 Sep;25 Suppl 3:iii49-56
pubmed: 25210086
Cancer Biol Ther. 2009 Dec;8(24):2406-16
pubmed: 20038816
Trends Biochem Sci. 2017 Jan;42(1):28-41
pubmed: 27765496
J Cell Sci. 2015 Mar 15;128(6):1166-79
pubmed: 25616897
J Cancer Res Ther. 2009 Sep;5 Suppl 1:S32-5
pubmed: 20009291
Cell Death Discov. 2015 Dec 21;1:15063
pubmed: 27551487
Sci Transl Med. 2012 Mar 7;4(124):124ra27
pubmed: 22323820
Medicine (Baltimore). 2017 Jun;96(26):e7325
pubmed: 28658143
Cancer Lett. 2015 Jan 28;356(2 Pt B):971-7
pubmed: 25444922
Rev Assoc Med Bras (1992). 2010 Jan-Feb;56(1):103-11
pubmed: 20339795
Cancer Res. 2006 Feb 1;66(3):1611-9
pubmed: 16452220
Clin Exp Metastasis. 2011 Dec;28(8):865-75
pubmed: 21842413
Mol Cell Oncol. 2015 Dec 10;3(3):e1117701
pubmed: 27314084
Oncol Res Treat. 2015;38(3):117-22
pubmed: 25792083
Oncoimmunology. 2018 May 31;7(8):e1466765
pubmed: 30221067